As a rebellious teenager growing up in the British town of Harpenden, Professor Helen Rees would sneak out to attend anti-apartheid talks. Today, she is a renowned scientist and chair of South Africa’s medicines regulator. Biénne Huisman chatted to Rees about her career, prioritising women’s reproductive health, and her role at the South African Health Products Regulatory Authority.
South Africa is expected to begin piloting the every-other-month HIV prevention shot early next year, according to the international medicine financing initiative Unitaid. New modelling shows that the injection could prevent as many as 52 000 new HIV infections in the next two decades. But to be cost-effective in South Africa, the research argues, the price of the injection must fall to levels drugmaker ViiV Healthcare says are unrealistic. Laura Lopez Gonzalez reports.
Unsafe sex, interpersonal violence, high body mass index, high systolic blood pressure, and alcohol consumption are the top risk factors for disease and death in South Africa, according to the Second Comparative Risk Assessment study conducted by the South African Medical Research Council’s Burden of Disease Research Unit. Nthusang Lefafa spoke to some of the researchers to unpack the findings.
Though South Africa has in some respects done well in the provision of sexual and reproductive health services for adolescent girls and young women, significant gaps remain. Tiyese Jeranji takes an in-depth look at the current policy landscape and asks how well the implementation of the policies measures up to their lofty ambitions.
A recently published report by the community-led clinic monitoring project, Ritshidze shows that while there have been pockets of improvements at some clinics in the Free State, there are key issues on which facilities’ performance has worsened, especially for people living with HIV. Refilwe Mochoari unpacks the report’s findings zooming in on the situation at Bloemspruit Clinic in Mangaung.
Professor Wendy Stevens believes ‘completely in the honesty of science’ and this, she says, has landed her in the naughty corner many times throughout her career. Biénne Huisman spoke to Stevens – a global leader in HIV and TB laboratory medicine about her career, what you choose when science and politics collide, and the value of swimming upstream.
The Treatment Action Campaign (TAC) elected new leadership at its recently held seventh national congress. Thabo Molelekwa attended the congress and asked TAC leaders about the organisation’s focus in 2022 and beyond.
Elri Voigt summarises some of the latest developments on long-acting therapies for HIV presented at the 2022 International AIDS conference.
Dr Thesla Palanee-Phillips is the Director of Clinical Trials at the Wits Reproductive Health and HIV Institute (Wits RHI) at the University of the Witwatersrand. As part of Spotlight’s Women in Health series, Elri Voigt spoke to her about what set her off into a career in science, the significance of the ASPIRE trial that she co-chaired, and juggling motherhood and her career.
It is estimated that in 2021, around 0.3% of sexually active people in the Western Cape were taking antiretroviral medicines to prevent HIV infection. This is substantially lower than the national estimate of 1%. Elsabé Brits asks why uptake in the Western Cape is lagging behind most other provinces.
One of the hot topics at the recently concluded AIDS 2022 conference held in Montreal, Canada, was how HIV prevention interventions such as pills or injections that prevent HIV infection should be made available to different groups of people. Tiyese Jeranji spoke to some local experts and an activist about the rich set of discussions.
The world stands at an inflection point once more in the war against HIV. For those of us working in the field in South Africa, especially, it feels eerily like the battle that was fought 25 years ago, writes Dr Liesl Page-Shipp.